Physician profile
Aruna Ray
NPI 1336418953
$1,637.93
in general payments reported to CMS, 2019-2025
11 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $108 · 2021: $152 · 2022: $203 · 2023: $362 · 2024: $379 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $436.39 | 2021-2025 | |
| Pfizer INC. | $330.41 | 2019-2025 | |
| Allergan, INC. | $245.45 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $123.23 | 2019-2024 | Xarelto |
| Ferring Pharmaceuticals INC. | $117.74 | 2023-2024 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $102.38 | 2021-2023 | Camzyos, Eliquis |
| Janssen Scientific Affairs, LLC | $81.11 | 2025 | Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $71.05 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $63.67 | 2023-2024 | Andexxa |
| Biomerieux INC | $51.89 | 2024 | Filmarray Bcid2 Control Panel M416 |
| Alexion Pharmaceuticals, INC. | $14.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.